ReviewInternational urogynecology journal2025
Long-Term Antibiotics for Disturbed Bladder Microbiome Disorders.
Review in International urogynecology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of Long-Term Antibiotic Therapy in Women with Chronic Recalcitrant Cystitis.International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisIn recent years, there has been significant progress in understanding bladder disorders and their connection to the bladder microbiome. Emerging evidence suggests that the bladder microbiome, which is unique to each individual, plays a pivotal role in maintaining bladder health. Disruptions to the normal microbiome composition have been associated with various pathological conditions such as recurrent urinary tract infections, interstitial cystitis, and chronic recalcitrant cystitis.
methodsWe completed a focused literature review to collect studies that evaluated the use of antibiotics for long-term treatment (more than 28 days) of infectious/inflammatory disturbed bladder microbiome DBM disorders.
resultsThis article reviews current literature on the composition of the bladder microbiome, describes the disorders associated with DBM, explores the utility of long-term antibiotics in managing DBM, and foresees future venues for DBM disorders research.
conclusionThis review has demonstrated encouraging outcomes regarding the use of long-term antibiotics in managing infectious disorders of DBM, such as recurrent urinary tract infections and chronic recalcitrant cystitis, while no benefit was seen in interstitial cystitis patients. The studies showed that long-term cephalexin, fluoroquinolones, and fosfomycin are well-tolerated and effective options, with cephalexin being favored given its low side-effect profile.
Indexed as
Identifiers
40327075What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.